Bacterial Vaginosis News and Research

RSS

Bacterial vaginosis (BV) is the name of a condition in women where the normal balance of bacteria in the vagina is disrupted and replaced by an overgrowth of certain bacteria. It is sometimes accompanied by discharge, odor, pain, itching, or burning.

New study finds certain bacterial species may increase HIV risk in women

In a recent study, scientists have identified seven species of vaginal bacteria that may significantly increase the risk of HIV infection in women.

26 Jan 2018

Certain bacterial species may increase HIV risk in women, finds new study

In a recent study, scientists have identified seven species of vaginal bacteria that may significantly increase the risk of HIV infection in women.

26 Jan 2018

UCLA professor offers 10 tips for college students to ensure good gynecologic health

For young women heading off to college, it can be a time filled with the excitement of living away from home. This new sense of independence should also include taking charge of one's own health, says Dr. Aparna Sridhar, an assistant professor of obstetrics and gynecology at the David Geffen School of Medicine at UCLA.

30 Aug 2017

Common periodontal pathogen may delay conception in young women, study finds

According to a study carried out at the University of Helsinki, a common periodontal pathogen may delay conception in young women.

13 Jun 2017

Study uncovers trigger for recurrent UTI infections

About half of all women will experience urinary tract infections in their lifetimes, and despite treatment, about a quarter will develop recurrent infections within six months of initial infection.

30 Mar 2017

Studies shed new light on why young women in South Africa experience high rates of HIV infection

Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, shedding new light on why young women in South Africa have high rates of HIV infection.

18 Jul 2016

Engineered vaginal Lactobacilli could reduce heterosexual HIV-1 transmission in women

A normal, predominant bacterial species of the healthy vaginal microbiota can be engineered for potential use as a novel protective agent against HIV-1 transmission in women, according to a new publication from scientists at Osel, Inc. and their collaborators.

24 Mar 2016

UNC researchers identify a type of vaginal bacteria that can protect women from HIV

Researchers at the University of North Carolina at Chapel Hill have identified a type of vaginal bacteria within the mucus of the female reproductive system that can protect women from HIV as well as other sexually transmitted infections.

9 Oct 2015

Cervicovaginal mucus effectively traps HIV particles

HIV particles are effectively trapped by the cervicovaginal mucus from women who harbor a particular vaginal bacteria species, Lactobacillus crispatus. The findings, published this week in mBio, an online open-access journal of the American Society for Microbiology, could lead to new ways to reduce or block vaginal transmission of HIV and other sexually transmitted infections (STIs).

7 Oct 2015

New study provides biological explanation for how DMPA increases risk of HIV infection

In recent years, evidence has been building that injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera or DMPA) is associated with an increased risk of HIV infection. Now a study published in the September 1st issue of mBio, an online open-access journal of the American Society for Microbiology, provides a biological explanation for the phenomenon.

2 Sep 2015

Laccure Pessary developed for treatment and prevention of bacterial vaginosis now ready for commercialisation

The Swedish company Laccure AB has developed a breakthrough women's health product that is effective, safe and user-friendly. Laccure's owners are now aiming to divest the company to a buyer with appropriate resources to launch the product.

1 Sep 2015

Symbiomix closes $41 million Series A financing and reports positive results from SYM-1219 Phase 2 trial

Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

6 May 2015

New microarray-based tool provides fast, reliable assessment of vaginal health

A new microarray-based tool, called VaginArray, offers the potential to provide a fast, reliable and low-cost assessment of vaginal health and diagnoses of infections. The research is published ahead of print March 2, in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.

19 Mar 2015

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.

4 Mar 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Population Council to present research on novel approaches to HIV prevention at HIV R4P 2014

The Population Council will present new research on novel approaches to HIV, sexually transmitted infections (STIs), and unintended pregnancy prevention at the HIV Research for Prevention Conference, (HIV R4P) in Cape Town, South Africa. HIV R4P, which runs 28–31 October, is the first global scientific meeting dedicated exclusively to research on biomedical HIV prevention.

27 Oct 2014

Researchers find good bacteria that protect women from HIV infection

Researchers at the University of Texas Medical Branch at Galveston by growing vaginal skin cells outside the body and studying the way they interact with "good and bad" bacteria, think they may be able to better identify the good bacteria that protect women from HIV infection and other sexually transmitted infections.

28 Mar 2014

Study finds cervicovaginal microbiota differs in women destined to have preterm birth

In a study to be presented on Feb. 6 at 3:15 p.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting-, in New Orleans, researchers will report that cervicovaginal (CV) microbiota differs in the late second and early third trimester in women destined to have a preterm birth.

4 Feb 2014

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Common species of bacteria contribute to bacterial vaginosis

New research at Washington University School of Medicine in St. Louis points to a common species of bacteria as an important contributor to bacterial vaginosis, a condition linked to preterm birth and increased risk of sexually transmitted diseases.

24 Apr 2013